OBJECTIVES: To conduct an SLR on humanistic burden, focusing on health-related quality of life (HRQOL), patient-reported outcomes (PRO), and utility/disutility values in patients with R/R FL.

METHODS: The SLR followed Cochrane methodologies to identify evidence on HRQOL, PROs, and utility/disutility values. Literature searches were conducted in September 2022 (limited to 2012‒2022) in MEDLINE, Embase, the Cochrane Library (CENTRAL), and PsycInfo. Only English-language publications were included.

RESULTS: Nineteen publications met the inclusion criteria as follows: 9 economic models, 7 health technology assessment (HTA) reports, 2 clinical trials, and 1 observational study. Four publications (2 in the R/R population and 2 in the third-line or later [3L+] setting) reported on HRQOL/PROs and 15 publications (12 in the R/R population and 3 in the 3L+ setting) reported on utility/disutility values. In all 4 HRQOL/PRO publications, the primary instrument used was the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym), with 1 study also using the 36-Item Short Form Survey (SF-36). In the observational study, patients with active relapsed FL demonstrated lower mean total FACT-Lym scores, indicating a poorer HRQOL compared with patients who achieved partial or complete response and those classified as disease free. In clinical trials conducted in the R/R population, the use of bendamustine plus obinutuzumab and tisagenlecleucel resulted in approximately 40%‒49% of patients experiencing a clinically meaningful improvement in HRQOL based on their FACT-Lym and/or SF-36 scores. The majority of economic models and HTAs relied on a single primary source (Wild et al. Value in Health 2006) for utility values, which were subsequently adjusted for the specific characteristics of each model and the population evaluated.

CONCLUSIONS: Data on HRQOL and utility/disutility values relevant to 3L+ treatment in R/R FL are scarce. Limited data are available for each subsequent line of therapy beyond the third line, highlighting the need for further research to inform future HTA submissions.